Sander van Deventer

Sander van Deventer

Company: uniQure

Job title: Executive Vice President, Research and Product Development


Dr. Sander van Deventer joined uniQure as Chief Scientific Officer, General Manager, Amsterdam in August 2017. In his current role as Executive Vice President, Operations, he is responsible for uniQure’s gene therapy research activities, as well as nonclinical development, process development, analytical development and vector development.

Dr. van Deventer was a co-founder of uniQure’s predecessor Amsterdam Molecular Therapeutics (AMT) in 1998 and previously served on the Company’s Board of Directors. He is a leading pioneer in the biotechnology industry and in the field of gene therapy.

Dr. van Deventer is currently Operating Partner at Forbion Capital partners and Professor of Translational Gastroenterology at Leiden University Medical Center. He also serves as member of the Board for Hookipa Pharma Inc. in Vienna, Austria.

Dr. van Deventer is a trained internist and board-certified gastroenterologist. He received a Ph.D. from the University of Amsterdam, and became Director of the Laboratory for Experimental Internal Medicine at the Academic Medical Center in Amsterdam in 1995.


Evaluating Immunogenic Responses in Systemic Administration: Determining the ‘Right’ Dose 3:15 pm

Discussing immunogenicity concerns in systemic administration of AAV vectors Determining relative impacts of capsid type and payload on immune response Optimizing dose levels to minimize immune response to the gene therapyRead more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.